Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | TP53 | P04637 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 12/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086546 | 0.89 | MAPT (0.45) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| Hydrochloric Acid SCHEMBL1086711 | 0.88 | MAPT (0.44) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL1086779 | 0.84 | ALDH1A1 (0.43) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2291215 | 0.83 | MAPT (0.45) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL1086175 | 0.83 | MAPT (0.40) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL16266145 | 0.81 | MAPT (0.44) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2289963 | 0.81 | TRPA1 (0.44) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2287174 | 0.81 | GAA (0.44) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2291150 | 0.81 | MAPT (0.43) | MAPTTP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2292180 | 0.80 | MAPT (0.42) | MAPTTP53SMN1; SMN2GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153649-B2 | 3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-8153649-B2 | 3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20100305142-A1 | 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305142-A1 | 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2097411-B1 | 3 -AMINO-IMIDAZO [1,2 -A]PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GMBH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2097411-B1 | 3 -AMINO-IMIDAZO [1,2 -A]PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GMBH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2097411-A1 | 3 -AMINO-IMIDAZO [1,2 -A]PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | Merck Patent GmbH (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008046497-A1 | 3 -AMINO-IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046497-A1 | 3 -AMINO-IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305142-A1 | 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES | SLC5A1, SLC5A2, GLP1R | MAPT 1231/4885TP53 4468/4885SMN1; SMN2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.